CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg
Drugsingle dose
NCT Number: NCT01735890
The objectives of this study are:
* To compare the safety profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg after a single oral administration in healthy male volunteers * To compare the pharmacokinetic profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg after a single oral administration in healthy male volunteers
Looking for future studies?
Notify Me20 year–45 year
Male
Interventional
Phase 1
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
single dose
Time frame: Up to 144 hours
Time frame: up to 144 hours
HK inno.N Corporation
Industry
A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet After a Single Oral Administration in Healthy Male Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07374406
Healthy
Jeonju, South Korea
View Trial DetailsNCT07365865
Deficient Keratinized Mucosa, Healthy
Cairo, Egypt
View Trial DetailsNCT04849923
Healthy
Winterthur, Canton of Zurich, Switzerland
View Trial DetailsNCT06744517
Behavior, Healthy
Toronto, Ontario, Canada
View Trial Details